Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Intensive Care Medicine
Erschienen in: Intensive Care Medicine 10/2022

06.09.2022 | Narrative Review

Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts

verfasst von: Faouzi Saliba, Rafael Bañares, Fin Stolze Larsen, Alexander Wilmer, Albert Parés, Steffen Mitzner, Jan Stange, Valentin Fuhrmann, Stefan Gilg, Tarek Hassanein, Didier Samuel, Josep Torner, Samir Jaber

Erschienen in: Intensive Care Medicine | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

The present narrative review on albumin dialysis provides evidence-based and expert opinion guidelines for clinicians caring for adult patients with different types of liver failure. The review was prepared by an expert panel of 13 members with liver and ntensive care expertise in extracorporeal liver support therapies for the management of patients with liver failure. The coordinating committee developed the questions according to their importance in the management of patients with liver failure. For each indication, experts conducted a comprehensive review of the literature aiming to identify the best available evidence and assessed the quality of evidence based on the literature and their experience. Summary statements and expert’s recommendations covered all indications of albumin dialysis therapy in patients with liver failure, timing and intensity of treatment, efficacy, technical issues related to the device and safety. The panel supports the data from the literature that albumin dialysis showed a beneficial effect on hepatic encephalopathy, refractory pruritus, renal function, reduction of cholestasis and jaundice. However, the trials lacked to show a clear beneficial effect on overall survival. A short-term survival benefit at 15 and 21 days respectively in acute and acute-on-chronic liver failure has been reported in recent studies. The technique should be limited to patients with a transplant project, to centers experienced in the management of advanced liver disease. The use of extracorporeal albumin dialysis could be beneficial in selected patients with advanced liver diseases listed for transplant or with a transplant project. Waiting future large randomized controlled trials, this panel experts’ statements may help careful patient selection and better treatment modalities.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Saliba F, Samuel D (2015) Artificial liver support: a real step forward. Minerva Med 106:35–43PubMed
2.
Camus C, Locher C, Saliba F, Goubaux B, Bonadona A, Lavayssiere L, Paugam C, Quinart A, Barbot O, Dharancy S, Delafosse B, Pichon N, Barraud H, Galbois A, Veber B, Cayot S, Souche B (2020) Outcome of patients treated with molecular adsorbent recirculating system albumin dialysis: a national multicenter study. JGH Open Open Access J Gastroenterol Hepatol 4:757–763
3.
Kanjo A, Ocskay K, Gede N, Kiss S, Szakács Z, Párniczky A, Mitzner S, Stange J, Hegyi P, Molnár Z (2021) Efficacy and safety of liver support devices in acute and hyperacute liver failure: a systematic review and network meta-analysis. Sci Rep 11:4189PubMedPubMedCentralCrossRef
4.
Alshamsi F, Alshammari K, Belley-Cote E, Dionne J, Albrahim T, Albudoor B, Ismail M, Al-Judaibi B, Baw B, Subramanian RM, Steadman R, Galusca D, Huang DT, Nanchal R, Al Quraini M, Yuan Y, Alhazzani W (2020) Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials. Intensive Care Med 46:1–16PubMedCrossRef
5.
Tandon R, Froghi S (2021) Artificial liver support systems. J Gastroenterol Hepatol 36:1164–1179PubMedCrossRef
6.
7.
Ronco C, Ricci Z, Husain-Syed F (2019) From multiple organ support therapy to extracorporeal organ support in critically ill patients. Blood Purif 48:99–105PubMedCrossRef
8.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926PubMedPubMedCentralCrossRef
9.
Bernardi M, Angeli P, Claria J, Moreau R, Gines P, Jalan R, Caraceni P, Fernandez J, Gerbes AL, O’Brien AJ, Trebicka J, Thevenot T, Arroyo V (2020) Albumin in decompensated cirrhosis: new concepts and perspectives. Gut 69:1127–1138PubMedCrossRef
10.
Peters TJ (1995) All about albumin: biochemistry, genetics, and medical applications. Academic Press, San Diego
11.
Quinlan GJ, Martin GS, Evans TW (2005) Albumin: biochemical properties and therapeutic potential. Hepatology 41:1211–1219PubMedCrossRef
12.
Sleep D (2015) Albumin and its application in drug delivery. Expert Opin Drug Deliv 12:793–812PubMedCrossRef
13.
14.
Bern M, Sand KM, Nilsen J, Sandlie I, Andersen JT (2015) The role of albumin receptors in regulation of albumin homeostasis: implications for drug delivery. J Control Release Off J Control Release Soc 211:144–162CrossRef
15.
Galis Z, Ghitescu L, Simionescu M (1988) Fatty acids binding to albumin increases its uptake and transcytosis by the lung capillary endothelium. Eur J Cell Biol 47:358–365PubMed
16.
Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, Triantafyllou E, Bernal W, Auzinger G, Shawcross D, Eefsen M, Bjerring PN, Clemmesen JO, Hockerstedt K, Frederiksen HJ, Hansen BA, Antoniades CG, Wendon J (2016) High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol 64:69–78PubMedCrossRef
17.
O’Grady JG, Gimson AE, O’Brien CJ, Pucknell A, Hughes RD, Williams R (1988) Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94:1186–1192PubMedCrossRef
18.
Mitzner S, Klammt S, Stange J, Schmidt R (2006) Albumin regeneration in liver support-comparison of different methods. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther 10:108–117
19.
Saliba F, Camus C, Durand F, Mathurin P, Letierce A, Delafosse B, Barange K, Perrigault PF, Belnard M, Ichai P, Samuel D (2013) Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med 159:522–531PubMedCrossRef
20.
Ilonen I, Koivusalo AM, Repo H, Höckerstedt K, Isoniemi H (2008) Cytokine profiles in acute liver failure treated with albumin dialysis. Artif Organs 32:52–60PubMed
21.
Schmidt LE, Tofteng F, Strauss GI, Larsen FS (2004) Effect of treatment with the Molecular Adsorbents Recirculating System on arterial amino acid levels and cerebral amino acid metabolism in patients with hepatic encephalopathy. Scand J Gastroenterol 39:974–980PubMedCrossRef
22.
Kantola T, Koivusalo AM, Höckerstedt K, Isoniemi H (2008) The effect of molecular adsorbent recirculating system treatment on survival, native liver recovery, and need for liver transplantation in acute liver failure patients. Transpl Int 21:857–866PubMedCrossRef
23.
Camus C, Lavoué S, Gacouin A, Compagnon P, Boudjéma K, Jacquelinet C, Thomas R, Le Tulzo Y (2009) Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: impact of the duration of therapy. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther 13:549–555
24.
Gerth HU, Pohlen M, Thölking G, Pavenstädt H, Brand M, Wilms C, Hüsing-Kabar A, Görlich D, Kabar I, Schmidt HH (2017) Molecular adsorbent recirculating system (MARS) in acute liver injury and graft dysfunction: results from a case-control study. PLoS One 12:e0175529PubMedPubMedCentralCrossRef
25.
MacDonald AJ, Subramanian RM, Olson JC, Speiser JL, Durkalski-Mauldin VL, Abraldes JG, Bigam DL, Flynn MM, Rapaka B, Shropshire BM, Vora RS, Karvellas CJ (2022) Use of the molecular adsorbent recirculating system in acute liver failure: results of a multicenter propensity score-matched study. Crit Care Med 50(2):286–295
26.
Arroyo V, Moreau R, Jalan R (2020) Acute-on-chronic liver failure. N Engl J Med 382:2137–2145PubMedCrossRef
27.
Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, Jalan R (2004) Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc 10:1109–1119
28.
Catalina MV, Barrio J, Anaya F, Salcedo M, Rincón D, Clemente G, Bañares R (2003) Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int Off J Int Assoc Study Liver 23(Suppl 3):39–43CrossRef
29.
Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, Fevery J, Nevens F (2006) Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care (Lond, Engl) 10:R108CrossRef
30.
Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R (2005) Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 43:142–148PubMedCrossRef
31.
Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner C, Stauber RE (2006) Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care (Lond, Engl) 10:R169CrossRef
32.
Banares R, Ibanez-Samaniego L, Torner JM, Pavesi M, Olmedo C, Catalina MV, Albillos A, Larsen FS, Nevens F, Hassanein T, Schmidt H, Heeman U, Jalan R, Moreau R, Arroyo V (2019) Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. Ther Adv Gastroenterol 12:1–12CrossRef
33.
Khuroo MS, Khuroo MS, Farahat KL (2004) Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc 10:1099–1106
34.
Liu Y, Kang YZ, Xia WZ, Zhou HC, Wang Y, Gao Y (2009) Artificial and bioartificial liver support systems for acute and acute-on-chronic liver failure: a meta-analysis. Nan Fang Yi Ke Da Xue Xue Bao 29:1529–1532PubMed
35.
Stutchfield BM, Simpson K, Wigmore SJ (2011) Systematic review and meta-analysis of survival following extracorporeal liver support. Br J Surg 98:623–631PubMedCrossRef
36.
Vaid A, Chweich H, Balk EM, Jaber BL (2012) Molecular adsorbent recirculating system as artificial support therapy for liver failure: a meta-analysis. ASAIO J 58:51–59PubMedCrossRef
37.
Zheng Z, Li X, Li Z, Ma X (2013) Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: a meta-analysis and meta-regression. Exp Ther Med 6:929–936PubMedPubMedCentralCrossRef
38.
Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Saliba F, Sauerbruch T, Klammt S, Ockenga J, Pares A, Wendon J, Brunnler T, Kramer L, Mathurin P, de la Mata M, Gasbarrini A, Mullhaupt B, Wilmer A, Laleman W, Eefsen M, Sen S, Zipprich A, Tenorio T, Pavesi M, Schmidt HH, Mitzner S, Williams R, Arroyo V (2013) Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 57:1153–1162PubMedCrossRef
39.
Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, Larsen FS, Gornbein J, Stange J, Blei AT (2007) Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46:1853–1862PubMedCrossRef
40.
Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mitzner S, Schmidt R, Stange J (2002) Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 36:949–958PubMed
41.
Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Löhr JM, Liebe S, Emmrich J, Korten G, Schmidt R (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc 6:277–286
42.
Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, Sarrazin C, Hoste E, Van Vlierberghe H, Escorsell A, Hafer C, Schreiner O, Galle PR, Mancini E, Caraceni P, Karvellas CJ, Salmhofer H, Knotek M, Gines P, Kozik-Jaromin J, Rifai K (2012) Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 142(782–789):e783
43.
Wong F, Raina N, Richardson R (2010) Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 59:381–386PubMedCrossRef
44.
Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V (2013) Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144(1426–1437):1437.e1421–1429
45.
European Association for the Study of the Liver (2017) EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67:145–172CrossRef
46.
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M (2019) Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 69:394–419PubMed
47.
Bachs L, Parés A, Elena M, Piera C, Rodés J (1992) Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102:2077–2080PubMedCrossRef
48.
Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR (1997) Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 113:1264–1269PubMedCrossRef
49.
Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ (2007) Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 45:666–674PubMedCrossRef
50.
Reig A, Sesé P, Parés A (2018) Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol 113:49–55PubMedCrossRef
51.
Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE (2017) Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 389:1114–1123PubMedCrossRef
52.
Kremer AE, Oude Elferink RP, Beuers U (2011) Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol 35:89–97PubMedCrossRef
53.
Parés A, Herrera M, Avilés J, Sanz M, Mas A (2010) Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 53:307–312PubMedCrossRef
54.
Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R (2012) ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther 35:696–704PubMedCrossRef
55.
Macia M, Avilés J, Navarro J, Morales S, García J (2003) Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med 114:62–64PubMedCrossRef
56.
Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, Rodés J (2004) Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 99:1105–1110PubMedCrossRef
57.
Bellmann R, Graziadei IW, Feistritzer C, Schwaighofer H, Stellaard F, Sturm E, Wiedermann CJ, Joannidis M (2004) Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc 10:107–114
58.
Lemoine M, Revaux A, Francoz C, Ducarme G, Brechignac S, Jacquemin E, Uzan M, Ganne-Carrie N (2008) Albumin liver dialysis as pregnancy-saving procedure in cholestatic liver disease and intractable pruritus. World J Gastroenterol 14:6572–6574PubMedPubMedCentralCrossRef
59.
Javouhey E, Ranchin B, Lachaux A, Boillot O, Martin X, Floret D, Cochat P (2009) Long-lasting extracorporeal albumin dialysis in a child with end-stage renal disease and severe cholestasis. Pediatr Transplant 13:235–239PubMedCrossRef
60.
Schaefer B, Schaefer F, Wittmer D, Engelmann G, Wenning D, Schmitt CP (2012) Molecular Adsorbents Recirculating System dialysis in children with cholestatic pruritus. Pediatr Nephrol 27:829–834PubMedCrossRef
61.
Horvatits T, Drolz A, Trauner M, Fuhrmann V (2019) Liver injury and failure in critical illness. Hepatology 70:2204–2215PubMedCrossRef
62.
Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Haider DG, Zauner C, Heinz G, Schellongowski P, Kluge S, Trauner M, Fuhrmann V (2016) Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit. Ann Intensive Care 6:61PubMedPubMedCentralCrossRef
63.
Drolz A, Saxa R, Scherzer T, Fuhrmann V (2011) Extracorporeal artificial liver support in hypoxic liver injury. Liver Int Off J Int Assoc Study Liver 31(Suppl 3):19–23CrossRef
64.
El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R (2004) First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 50:332–337PubMedCrossRef
65.
Fuhrmann V, Herkner H, Roedl K, Drolz A, Horvatits T, Horvatits K, Jarczak D, Zauner C, Schellongowski P, Heinz G, Trauner M, Kluge S (2019) Behandlung von sekundärem Leberversagen mit dem MARS®-System - eine randomisiert-kontrollierte Studie. In: Editor (ed)^(eds) Book Behandlung von sekundärem Leberversagen mit dem MARS®-System - eine randomisiert-kontrollierte Studie. City, pp 11–12
66.
van Mierlo KM, Schaap FG, Dejong CH, Olde Damink SW (2016) Liver resection for cancer: new developments in prediction, prevention and management of postresectional liver failure. J Hepatol 65:1217–1231PubMedCrossRef
67.
Catalina MV, Barrio J, Anaya F, Salcedo M, Rincon D, Clemente G, Banares R (2003) Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int Off J Int Assoc Study Liver 23(Suppl 3):39–43CrossRef
68.
Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R (2005) Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 43:142–148
69.
Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner C, Stauber RE (2006) Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 10:R169PubMedPubMedCentralCrossRef
70.
Gilg (2016) Albumin dialysis with mars in post-hepatectomy liver failure (PHLF): experiences from two HPB centers. Surg Curr Res 6: 252:1–6
71.
Gilg S, Sparrelid E, Saraste L, Nowak G, Wahlin S, Strömberg C, Lundell L, Isaksson B (2018) The molecular adsorbent recirculating system in posthepatectomy liver failure: results from a prospective phase I study. Hepatol Commun 2:445–454PubMedPubMedCentralCrossRef
72.
Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, Durand F (2005) The “50-50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 242:824–828PubMedPubMedCentralCrossRef
73.
Sparrelid E, Gilg S, van Gulik TM (2020) Systematic review of MARS treatment in post-hepatectomy liver failure. HPB (Oxf) 22:950–960CrossRef
74.
Beyls C, Malaquin S, Huette P, Mary A, Besserve P, Roger PA, Bernasinski M, Guilbart M, Abou-Arab O, Dupont H, Mahjoub Y (2021) Hemodynamic impact of molecular adsorbent recirculating system in refractory vasoplegic shock due to calcium channel blocker poisoning. Int J Artif Organs 44(12):944–951
75.
Pichon N, Dugard A, Clavel M, Amiel JB, François B, Vignon P (2012) Extracorporeal albumin dialysis in three cases of acute calcium channel blocker poisoning with life-threatening refractory cardiogenic shock. Ann Emerg Med 59:540–544PubMedCrossRef
76.
Hassoun J, Hammer N, Magini G, Ponte B, Ongaro M, Rougemont AL, Goossens N, Frossard JL, Spahr L (2021) Management of acute Wilsonian hepatitis with severe hemolysis: a successful combination of chelation and MARS dialysis. Case Rep Hepatol 2021:5583654
77.
Faybik P, Hetz H, Baker A, Bittermann C, Berlakovich G, Werba A, Krenn CG, Steltzer H (2003) Extracorporeal albumin dialysis in patients with Amanita phalloides poisoning. Liver Int Off J Int Assoc Study Liver 23(Suppl 3):28–33CrossRef
78.
De Bruyn T, Meijers B, Evenepoel P, Laub R, Willems L, Augustijns P, Annaert P (2012) Stability of therapeutic albumin solutions used for molecular adsorbent recirculating system-based liver dialysis. Artif Organs 36:29–41PubMedCrossRef
79.
Krisper P, Tiran B, Fliser D, Haditsch B, Stadlbauer V, Otto R, Ernst T, Kretschmer U, Stauber RE, Haller H, Holzer H, Manns MP, Rifai K (2010) Efficacy and safety of anticoagulation with heparin versus heparin plus epoprostenol in patients undergoing extracorporeal liver support with Prometheus. Artif Organs 34:84–88PubMedCrossRef
80.
Tan HK, Yang WS, Chow P, Lui HF, Choong HL, Wong KS (2007) Anticoagulation minimization is safe and effective in albumin liver dialysis using the molecular adsorbent recirculating system. Artif Organs 31:193–199PubMedCrossRef
81.
Faybik P, Hetz H, Mitterer G, Krenn CG, Schiefer J, Funk GC, Bacher A (2011) Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med 39:273–279PubMedCrossRef
82.
Meijers B, Laleman W, Vermeersch P, Nevens F, Wilmer A, Evenepoel P (2012) A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System. Crit Care (Lond, Engl) 16:R20CrossRef
83.
Tan HK (2004) Molecular adsorbent recirculating system (MARS). Ann Acad Med Singap 33:329–335PubMed
84.
Sponholz C, Matthes K, Rupp D, Backaus W, Klammt S, Karailieva D, Bauschke A, Settmacher U, Kohl M, Clemens MG, Mitzner S, Bauer M, Kortgen A (2016) Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure—a prospective, randomised crossover study. Crit Care (Lond, Engl) 20:2CrossRef
85.
Dyla A, Mielnicki W, Bartczak J, Zawada T, Garba P (2017) Effectiveness and safety assessment of citrate anticoagulation during albumin dialysis in comparison to other methods of anticoagulation. Artif Organs 41:818–826PubMedCrossRef
86.
Thai C, Oben C, Wagener G (2020) Coagulation, hemostasis, and transfusion during liver transplantation. Best Pract Res Clin Anaesthesiol 34:79–87PubMedCrossRef
87.
Evenepoel P, Laleman W, Wilmer A, Claes K, Kuypers D, Bammens B, Nevens F, Vanrenterghem Y (2006) Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif Organs 30:276–284PubMedCrossRef
88.
Schneider AG, Journois D, Rimmelé T (2017) Complications of regional citrate anticoagulation: accumulation or overload? Crit Care (Lond, Engl) 21:281CrossRef
89.
Weiler S, Vogelsinger H, Joannidis M, Dunzendorfer S, Bellmann R (2011) Influence of albumin dialysis on pharmacokinetics of amphotericin B colloidal dispersion and amphotericin B lipid complex. Artif Organs 35:667–671PubMedCrossRef
90.
Aguilar G, Azanza JR, Sádaba B, Badenes R, Ferrando C, Delgado C, Hernández J, Parra MA, Puig J, Carbonell JA, Navarro D, Belda FJ (2014) Pharmacokinetics of anidulafungin during albumin dialysis. Crit Care (Lond, Engl) 18:422CrossRef
91.
Personett HA, Larson SL, Frazee EN, Nyberg SL, El-Zoghby ZM (2015) Extracorporeal elimination of piperacillin/tazobactam during molecular adsorbent recirculating system therapy. Pharmacotherapy 35:e136-139PubMedCrossRef
92.
Ruggero MA, Argento AC, Heavner MS, Topal JE (2013) Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure. Transpl Infect Dis Off J Transplant Soc 15:214–218CrossRef
93.
Personett HA, Larson SL, Frazee EN, Nyberg SL, Leung N, El-Zoghby ZM (2014) Impact of molecular adsorbent recirculating system therapy on tacrolimus elimination: a case report. Transplant Proc 46:2440–2442PubMedCrossRef
94.
Falkensteiner C, Kortgen A, Leonhardt J, Bauer M, Sponholz C (2021) Comparison of albumin dialysis devices molecular adsorbent recirculating system and ADVanced Organ Support system in critically ill patients with liver failure—a retrospective analysis. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther 25:225–236
95.
Fuhrmann V, Weber T, Roedl K, Motaabbed J, Tariparast A, Jarczak D, de Garibay APR, Kluwe J, Boenisch O, Herkner H, Kellum JA, Kluge S (2020) Advanced organ support (ADVOS) in the critically ill: first clinical experience in patients with multiple organ failure. Ann Intensive Care 10:96PubMedPubMedCentralCrossRef
96.
Tan EX, Wang MX, Pang J, Lee GH (2020) Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review. World J Gastroenterol 26:219–245PubMedPubMedCentralCrossRef
97.
Schmidt LE, Wang LP, Hansen BA, Larsen FS (2003) Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc 9:290–297
98.
Novelli G, Rossi M, Pretagostini M, Pugliese F, Ruberto F, Novelli L, Nudo F, Bussotti A, Corradini S, Martelli S, Berloco PB (2005) One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc 37:2557–2559PubMedCrossRef
99.
El Banayosy A, Cobaugh D, Pauly A, Kizner L, Korfer R (2007) Albumindialyse bei patienten mit sekundärem leberversagen nach kariogenem schock. Intensivemed 44:149–157CrossRef
100.
Gerth HU, Pohlen M, Thölking G, Pavenstädt H, Brand M, Hüsing-Kabar A, Wilms C, Maschmeier M, Kabar I, Torner J, Pavesi M, Arroyo V, Banares R, Schmidt HHJ (2017) Molecular adsorbent recirculating system can reduce short-term mortality among patients with acute-on-chronic liver failure—a retrospective analysis. Crit Care Med 45:1616–1624PubMedPubMedCentralCrossRef
Metadaten
Titel
Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts
verfasst von
Faouzi Saliba
Rafael Bañares
Fin Stolze Larsen
Alexander Wilmer
Albert Parés
Steffen Mitzner
Jan Stange
Valentin Fuhrmann
Stefan Gilg
Tarek Hassanein
Didier Samuel
Josep Torner
Samir Jaber
Publikationsdatum
06.09.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 10/2022
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-022-06802-1

Weitere Artikel der Ausgabe 10/2022

Intensive Care Medicine 10/2022 Zur Ausgabe

Special Issue Insight

Invasive arterial pressure monitoring: much more than mean arterial pressure!

Special Issue Insight

Timing of early mobilization to optimize outcomes in mechanically ventilated ICU patients

Special Issue Insight

Continuous intra-abdominal pressure: is it ready for prime time?

Review

Respiratory indications for ECMO: focus on COVID-19

Editorial

Machines that save lives in intensive care: why a special issue in ICM?

Correction

Correction to: Central venous pressure (CVP)

Neu im Fachgebiet AINS

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise